Oruka Therapeutics (NASDAQ:ORKA) CEO Lawrence Otto Klein Sells 75,000 Shares

Oruka Therapeutics, Inc. (NASDAQ:ORKA) CEO Lawrence Otto Klein sold 75,000 shares of the business’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $91.83, for a total transaction of $6,887,250.00. Following the sale, the chief executive officer directly owned 925,580 shares of the company’s stock, valued at approximately $84,996,011.40. This represents a 7.50% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Lawrence Otto Klein also recently made the following trade(s):

• On Monday, June 15th, Lawrence Otto Klein sold 1,729 shares of Oruka Therapeutics stock. The stock was sold at an average price of $69.69, for a total transaction of $120,494.01.

Oruka Therapeutics Trading Down 0.6%

Shares of Oruka Therapeutics stock opened at $92.11 on Wednesday. The stock has a market capitalization of $6.10 billion, a price-to-earnings ratio of -45.37 and a beta of -0.34. Oruka Therapeutics, Inc. has a twelve month low of $14.66 and a twelve month high of $115.51. The business’s 50 day simple moving average is $94.92 and its 200-day simple moving average is $68.59.

Oruka Therapeutics (NASDAQ:ORKA) last posted its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). Sell-side analysts predict that Oruka Therapeutics, Inc. will post -2.33 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on ORKA shares. Wedbush reaffirmed an “outperform” rating and issued a $165.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, August 11th. UBS Group upped their target price on Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. BTIG Research reaffirmed a “buy” rating and set a $151.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. HC Wainwright reaffirmed a “buy” rating and issued a $120.00 price objective on shares of Oruka Therapeutics in a research note on Monday, August 3rd. Finally, Wall Street Zen cut Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $134.30.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Algert Global LLC raised its holdings in shares of Oruka Therapeutics by 3.5% during the second quarter. Algert Global LLC now owns 5,380 shares of the company’s stock worth $512,000 after acquiring an additional 180 shares in the last quarter. Nykredit A S purchased a new stake in shares of Oruka Therapeutics during the 2nd quarter worth about $29,000. Royal Bank of Canada grew its stake in shares of Oruka Therapeutics by 47.2% in the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after buying an additional 365 shares in the last quarter. Kennedy Capital Management LLC increased its holdings in Oruka Therapeutics by 0.9% in the fourth quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company’s stock worth $1,476,000 after buying an additional 420 shares during the last quarter. Finally, AlphaCentric Advisors LLC increased its holdings in Oruka Therapeutics by 5.8% in the first quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company’s stock worth $564,000 after buying an additional 626 shares during the last quarter. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.